- Home
- CING vs NRXP Comparison
CING vs NRXP Comparison
Compare CING & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- NRXP
- Stock Information
- Founded
- CING 2012
- NRXP 2015
- Country
- CING United States
- NRXP United States
- Employees
- CING N/A
- NRXP N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- CING Health Care
- NRXP Health Care
- Exchange
- CING Nasdaq
- NRXP Nasdaq
- Market Cap
- CING 13.5M
- NRXP 14.8M
- IPO Year
- CING 2021
- NRXP N/A
- Fundamental
- Price
- CING $4.10
- NRXP $1.52
- Analyst Decision
- CING Strong Buy
- NRXP Strong Buy
- Analyst Count
- CING 3
- NRXP 3
- Target Price
- CING $96.00
- NRXP $31.67
- AVG Volume (30 Days)
- CING 92.0K
- NRXP 288.4K
- Earning Date
- CING 11-07-2024
- NRXP 11-14-2024
- Dividend Yield
- CING N/A
- NRXP N/A
- EPS Growth
- CING N/A
- NRXP N/A
- EPS
- CING N/A
- NRXP N/A
- Revenue
- CING N/A
- NRXP N/A
- Revenue This Year
- CING N/A
- NRXP N/A
- Revenue Next Year
- CING N/A
- NRXP N/A
- P/E Ratio
- CING N/A
- NRXP N/A
- Revenue Growth
- CING N/A
- NRXP N/A
- 52 Week Low
- CING $1.80
- NRXP $1.10
- 52 Week High
- CING $152.40
- NRXP $7.33
- Technical
- Relative Strength Index (RSI)
- CING 41.97
- NRXP 66.79
- Support Level
- CING $4.09
- NRXP $1.17
- Resistance Level
- CING $4.39
- NRXP $1.23
- Average True Range (ATR)
- CING 0.20
- NRXP 0.11
- MACD
- CING -0.02
- NRXP 0.04
- Stochastic Oscillator
- CING 0.22
- NRXP 58.57
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.